In September, the European Medicines Agency's committee recommended against renewing the conditional marketing authorisation for Blenrep, a setback to the key oncology unit GSK has been looking to strengthen. GSK said last month that Blenrep, which was the second-largest contributor to GSK's oncology business in 2022, had reached a key goal in a separate late-stage trial.